Infliximab in Crohn's disease-associated toxic megacolon.

Abstract

Refractory medical treatment of Crohn disease-associated toxic megacolon usually requires surgery, which carries substantial morbidity and mortality. We report a case of a woman with steroid and antibiotic-refractory fulminant Crohn colitis and ileitis, complicated by a toxic megacolon, who was successfully treated with infliximab. Infliximab induced rapid clinical response and remission, thereby avoiding emergency (ileo) colectomy. This is the first report of treatment of Crohn disease-associated toxic megacolon with infliximab.

• Authors: Erwin-Jan M van Geenen, David B Sachar
• Journal: Journal of clinical gastroenterology (J Clin Gastroenterol) Vol. 46 Issue 4 Pg. 321-3 (Apr 2012) ISSN: 1539-2031 [Electronic] United States
• PMID: 21857531 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Gastrointestinal Agents
• Infliximab

Topics

• Adult
• Antibodies, Monoclonal (therapeutic use)
• Crohn Disease (complications, drug therapy)
• Female
• Gastrointestinal Agents (therapeutic use)
• Humans
• Infliximab
• Megacolon, Toxic (drug therapy, etiology)
• Treatment Outcome